The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.65
Bid: 3.50
Ask: 3.80
Change: 0.25 (7.35%)
Spread: 0.30 (8.571%)
Open: 3.43
High: 3.65
Low: 3.43
Prev. Close: 3.40
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

8 Apr 2015 15:47

RNS Number : 6554J
Allergy Therapeutics PLC
08 April 2015
 



 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Allergy Therapeutics Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

No

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

No

An event changing the breakdown of voting rights

No

Other (please specify):

No

3. Full name of person(s) subject to thenotification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

31 March 2015

6. Date on which issuer notified:

01 April 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB00B02LCQ05

18,016,209

18,016,209

30,685,209

5.62%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

30,685,209

5.62%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Invesco Asset Management Limited - 30,685,209

Proxy Voting:

10. Name of the proxy holder:

Invesco Limited

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

14. Contact name:

Philippa Sadler

15. Contact telephone number:

01491 417 447

 

Note: Annex should only be submitted to the FCA not the issuer

Annex: Notification of major interests in sharesxxii

A: Identity of the persons or legal entity subject to the notification obligation

Full name

(including legal form of legal entities)

 

Contact address

(registered office for legal entities)

 

Phone number & email

 

Other useful information

(at least legal representative for legal persons)

 

B: Identity of the notifier, if applicable

Full name

 

Invesco (UK) Limited

Contact address

 

Perpetual Park, Perpetual Park Drive, Henley-on-Thames. Oxon. RG9 1HH

Phone number & email

 

01491 417 000

Other useful information

(e.g. functional relationship with the person or legal entity subject to the notification obligation)

Invesco (UK) Limited

C: Additional information

For notes on how to complete form TR-1 please see the FCA website.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUWSSRVBASRAR
Date   Source Headline
2nd Feb 20187:15 amRNSHardman Research: Growth in a tough market
31st Jan 20187:00 amRNSTrading Update
10th Jan 20183:19 pmRNSHoldings in Company
9th Jan 20187:00 amRNSPQ Birch Phase III trial completes recruitment
12th Dec 20177:00 amRNSCo-development agreement with Ergomed plc
7th Dec 20175:08 pmRNSHolding(s) in Company
22nd Nov 201711:36 amRNSResult of AGM
21st Nov 20177:00 amRNSBlock Listing Application
13th Nov 20177:00 amRNSAllergy Therapeutics to Present at Jefferies 2017
7th Nov 201712:59 pmRNSDirector/PDMR Shareholding
7th Nov 201711:54 amRNSDirector/PDMR Shareholding
19th Oct 20174:14 pmRNSPublication of Annual Report and notice of AGM
19th Oct 20177:00 amRNSCommencement of dosing in PQ Grass Phase II Trial
12th Oct 20175:39 pmRNSHolding(s) in Company
12th Oct 20172:55 pmRNSDirector/PDMR Shareholding
10th Oct 20177:15 amRNSHardman Research: Continuing to gain market share
28th Sep 20177:00 amRNSPreliminary Results
18th Sep 20177:00 amRNSApproval for PQ Grass Phase II trial
11th Sep 20177:00 amRNSExpansion of Clinical Development and R&D teams
15th Aug 20177:00 amRNSNotice of Results
18th Jul 20177:00 amRNSTrading Update
6th Jul 20177:00 amRNSPublication of adjuvant studies in journals
27th Jun 20177:00 amRNSInvestor and analyst site visits
19th Jun 20177:00 amRNSSatellite Symposium at EAACI 2017
6th Jun 20177:00 amRNSDirectorate changes
2nd Jun 201712:55 pmRNSHolding(s) in Company
13th Apr 20177:00 amRNSIssue of Equity
5th Apr 20177:15 amRNSHardman Research: Development across portfolio
29th Mar 20177:00 amRNSInterim Results for six months ended 31 Dec 2016
16th Mar 20177:00 amRNSFirst Patient in Pivotal Phase III Birch Study
9th Mar 20177:00 amRNSNotice of Interim Results
14th Feb 20177:00 amRNSHouse Dust Mite Allergy Vaccine Gains CTA Approval
8th Feb 20177:00 amRNSDirectorate Change
1st Feb 20177:00 amRNSPositive Efficacy & Safety Data in Peanut Vaccine
20th Jan 20177:15 amRNSHardman Research: Investment driving market share
19th Jan 20177:00 amRNSTrading Update
30th Dec 20162:31 pmRNSGrant of Awards
24th Nov 20165:23 pmRNSResult of AGM
2nd Nov 20167:00 amRNSEU Patent Office grants patent for MCT
27th Oct 20161:10 pmRNSIssue of equity in respect of exercise of options
24th Oct 20161:35 pmRNSAnnual Report and Accounts
10th Oct 20167:00 amRNSNew data from novel adjuvant system
3rd Oct 201611:28 amRNSIssue of equity in respect of exercise of options
29th Sep 201612:40 pmRNSDirector/PDMR Shareholding
28th Sep 20167:00 amRNSDirector/PDMR Shareholding
26th Sep 201611:59 amRNSDirector/PDMR Shareholding
26th Sep 201610:46 amRNSHardman Research: Performance drives market share
26th Sep 20167:00 amRNSAllergy Therapeutics Preliminary Results
20th Sep 20164:58 pmRNSIssue of equity in respect of exercise of options
5th Sep 20167:00 amRNSNotice of Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.